Works matching AU Witzens‐Harig, Mathias

Results: 66
    1
    2
    3

    Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma.

    Published in:
    European Journal of Haematology, 2008, v. 81, n. 1, p. 26, doi. 10.1111/j.1600-0609.2008.01076.x
    By:
    • Belle, Sebastian;
    • Fang Han;
    • Condomines, Maud;
    • Christensen, Olaf;
    • Witzens-Harig, Mathias;
    • Kasper, Bernd;
    • Kleist, Christian;
    • Terness, Peter;
    • Moos, Marion;
    • Cremer, Friedrich;
    • Hose, Dirk;
    • Ho, Anthony D.;
    • Goldschmidt, Hartmut;
    • Klein, Bernard;
    • Hundemer, Michael
    Publication type:
    Article
    4

    Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial.

    Published in:
    2019
    By:
    • König, Laila;
    • Dreyling, Martin;
    • Dürig, Jan;
    • Engelhard, Marianne;
    • Hohloch, Karin;
    • Viardot, Andreas;
    • Witzens-Harig, Mathias;
    • Kieser, Meinhard;
    • Klapper, Wolfram;
    • Pott, Christiane;
    • Herfarth, Klaus
    Publication type:
    journal article
    5
    6
    7
    8
    9
    10
    11
    12
    13

    Radiation and Dose‐densification of R‐CHOP in Primary Mediastinal B‐cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial.

    Published in:
    HemaSphere, 2023, v. 7, n. 7, p. e917, doi. 10.1097/HS9.0000000000000917
    By:
    • Held, Gerhard;
    • Thurner, Lorenz;
    • Poeschel, Viola;
    • Ott, German;
    • Schmidt, Christian;
    • Christofyllakis, Konstantinos;
    • Viardot, Andreas;
    • Borchmann, Peter;
    • Engel‐Riedel, Walburga;
    • Frickhofen, Norbert;
    • Nickelsen, Maike;
    • Shpilberg, Ofer;
    • Witzens‐Harig, Mathias;
    • Griesinger, Frank;
    • Krammer‐Steiner, Beate;
    • Neubauer, Andreas;
    • de Nully Brown, Peter;
    • Federico, Massimo;
    • Glass, Bertram;
    • Schmitz, Norbert
    Publication type:
    Article
    14

    Radiation and Dose‐densification of R‐CHOP in Aggressive B‐cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study.

    Published in:
    HemaSphere, 2023, v. 7, n. 7, p. e904, doi. 10.1097/HS9.0000000000000904
    By:
    • Thurner, Lorenz;
    • Ziepert, Marita;
    • Berdel, Christian;
    • Schmidt, Christian;
    • Borchmann, Peter;
    • Kaddu‐Mulindwa, Dominic;
    • Viardot, Andreas;
    • Witzens‐Harig, Mathias;
    • Dierlamm, Judith;
    • Haenel, Mathias;
    • Metzner, Bernd;
    • Wulf, Gerald;
    • Lengfelder, Eva;
    • Keller, Ulrich B.;
    • Frickhofen, Norbert;
    • Nickelsen, Maike;
    • Gaska, Tobias;
    • Griesinger, Frank;
    • Mahlberg, Rolf;
    • Marks, Reinhard
    Publication type:
    Article
    15

    First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial.

    Published in:
    HemaSphere, 2022, v. 6, n. 12, p. e808, doi. 10.1097/HS9.0000000000000808
    By:
    • Braulke, Friederike;
    • Zettl, Florian;
    • Ziepert, Marita;
    • Viardot, Andreas;
    • Kahl, Christoph;
    • Prange-Krex, Gabriele;
    • Korfel, Agnieszka;
    • Dreyling, Martin;
    • Bott, Alexander;
    • Wedding, Ulrich;
    • Reichert, Dietmar;
    • de Wit, Maike;
    • Hartmann, Frank;
    • Poeschel, Viola;
    • Schmitz, Norbert;
    • Witzens-Harig, Mathias;
    • Klapper, Wolfram;
    • Rosenwald, Andreas;
    • Wulf, Gerald;
    • Altmann, Bettina
    Publication type:
    Article
    16

    Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.

    Published in:
    Leukemia & Lymphoma, 2022, v. 63, n. 2, p. 326, doi. 10.1080/10428194.2021.1975193
    By:
    • Kaddu-Mulindwa, Dominic;
    • Lesan, Vadim;
    • Berdel, Christian;
    • Stilgenbauer, Stephan;
    • Bewarder, Moritz;
    • Thurner, Lorenz;
    • Witzens-Harig, Mathias;
    • Viardot, Andreas;
    • Soekler, Martin;
    • Keller, Ulrich;
    • Truemper, Lorenz;
    • Christofyllakis, Konstantinos;
    • Fleser, Octavian;
    • Bittenbring, Joerg Thomas;
    • Poeschel, Viola;
    • Held, Gerhard;
    • Jagoda, Philippe
    Publication type:
    Article
    17

    Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.

    Published in:
    Leukemia & Lymphoma, 2017, v. 58, n. 12, p. 2824, doi. 10.1080/10428194.2017.1326034
    By:
    • Hess, Georg;
    • Rule, Simon;
    • Jurczak, Wojciech;
    • Jerkeman, Mats;
    • Santucci Silva, Rodrigo;
    • Rusconi, Chiara;
    • Caballero, Dolores;
    • Joao, Cristina;
    • Witzens-Harig, Mathias;
    • Bence-Bruckler, Isabelle;
    • Cho, Seok-Goo;
    • Zhou, Wenjiong;
    • Goldberg, Jenna D.;
    • Trambitas, Cristina;
    • Enny, Christopher;
    • Vermeulen, Jessica;
    • Traina, Shana;
    • Chiou, Chiun-Fang;
    • Diels, Joris;
    • Dreyling, Martin
    Publication type:
    Article
    18
    19
    20
    21

    The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.

    Published in:
    Nature Genetics, 2013, v. 45, n. 5, p. 522, doi. 10.1038/ng.2583
    By:
    • Weinhold, Niels;
    • Johnson, David C;
    • Chubb, Daniel;
    • Chen, Bowang;
    • Försti, Asta;
    • Hosking, Fay J;
    • Broderick, Peter;
    • Ma, Yussanne P;
    • Dobbins, Sara E;
    • Hose, Dirk;
    • Walker, Brian A;
    • Davies, Faith E;
    • Kaiser, Martin F;
    • Li, Ni L;
    • Gregory, Walter A;
    • Jackson, Graham H;
    • Witzens-Harig, Mathias;
    • Neben, Kai;
    • Hoffmann, Per;
    • Nöthen, Markus M
    Publication type:
    Article
    22
    23

    Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer.

    Published in:
    Cancers, 2020, v. 12, n. 6, p. 1604, doi. 10.3390/cancers12061604
    By:
    • Kriegsmann, Mark;
    • Haag, Christian;
    • Weis, Cleo-Aron;
    • Steinbuss, Georg;
    • Warth, Arne;
    • Zgorzelski, Christiane;
    • Muley, Thomas;
    • Winter, Hauke;
    • Eichhorn, Martin E.;
    • Eichhorn, Florian;
    • Kriegsmann, Joerg;
    • Christopolous, Petros;
    • Thomas, Michael;
    • Witzens-Harig, Mathias;
    • Sinn, Peter;
    • von Winterfeld, Moritz;
    • Heussel, Claus Peter;
    • Herth, Felix J. F.;
    • Klauschen, Frederick;
    • Stenzinger, Albrecht
    Publication type:
    Article
    24

    Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma.

    Published in:
    Annals of Hematology, 2020, v. 99, n. 12, p. 2837, doi. 10.1007/s00277-020-04021-6
    By:
    • Davies, Andrew;
    • Trask, Peter;
    • Demeter, Judit;
    • Florschütz, Axel;
    • Hänel, Mathias;
    • Kinoshita, Tomohiro;
    • Pettengell, Ruth;
    • Quach, Hang;
    • Robinson, Stephen;
    • Sadullah, Shalal;
    • Sancho, Juan-Manuel;
    • Udvardy, Miklos;
    • Witzens-Harig, Mathias;
    • Knapp, Andrea;
    • Liu, Wenxin
    Publication type:
    Article
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35

    Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 5, p. 1472, doi. 10.1007/s10637-020-00916-3
    By:
    • Kroschinsky, Frank;
    • Middeke, Jan Moritz;
    • Janz, Martin;
    • Lenz, Georg;
    • Witzens-Harig, Mathias;
    • Bouabdallah, Reda;
    • La Rosée, Paul;
    • Viardot, Andreas;
    • Salles, Gilles;
    • Kim, Seok Jin;
    • Kim, Tae Min;
    • Ottmann, Oliver;
    • Chromik, Joerg;
    • Quinson, Anne-Marie;
    • von Wangenheim, Ute;
    • Burkard, Ute;
    • Berk, Andreas;
    • Schmitz, Norbert
    Publication type:
    Article
    36
    37
    38
    39
    40
    41
    42
    43
    44

    Sorafenib in patients with refractory or recurrent multiple myeloma.

    Published in:
    Hematological Oncology, 2013, v. 31, n. 4, p. 197, doi. 10.1002/hon.2043
    By:
    • Yordanova, Anna;
    • Hose, Dirk;
    • Neben, Kai;
    • Witzens‐Harig, Mathias;
    • Gütgemann, Ines;
    • Raab, Marc‐Steffen;
    • Moehler, Thomas;
    • Goldschmidt, Hartmut;
    • Schmidt‐Wolf, Ingo GH
    Publication type:
    Article
    45
    46
    47

    A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.

    Published in:
    British Journal of Haematology, 2022, v. 198, n. 3, p. 482, doi. 10.1111/bjh.18161
    By:
    • Hess, Georg;
    • Hüttmann, Andreas;
    • Witzens‐Harig, Mathias;
    • Dreyling, Martin H.;
    • Keller, Ulrich;
    • Marks, Reinhard;
    • Ernst, Thomas;
    • Pott, Christiane;
    • Viardot, Andreas;
    • Frontzek, Fabian;
    • Trautmann, Marcel;
    • Ruckes, Christian;
    • Deuster, Oliver;
    • Rosenwald, Andreas;
    • Theobald, Matthias;
    • Lenz, Georg
    Publication type:
    Article
    48

    Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial.

    Published in:
    British Journal of Haematology, 2015, v. 171, n. 5, p. 710, doi. 10.1111/bjh.13652
    By:
    • Witzens‐Harig, Mathias;
    • Benner, Axel;
    • McClanahan, Fabienne;
    • Klemmer, Jennifer;
    • Brandt, Julia;
    • Brants, Elke;
    • Rieger, Michael;
    • Meissner, Julia;
    • Hensel, Manfred;
    • Neben, Kai;
    • Dreger, Peter;
    • Lengfelder, Eva;
    • Schmidt‐Wolf, Ingo;
    • Krämer, Alwin;
    • Ho, Anthony D.
    Publication type:
    Article
    49
    50